Skip to main content
Premium Trial:

Request an Annual Quote

Toronto University Group Collaborates with Thermo Fisher on Cancer Biomarker Study

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific will handle mass spectrometry projects for Toronto’s University Health Network in a proteomics initiative focused on finding cancer biomarkers in cell lines, the company said today.
 
The Canadian researchers will work with Thermo Fisher’s Biomarker Research Initiatives in Mass Spectrometry, or BRIMS, Center in Cambridge, Mass., and will use the company’s LTQ Orbitrap and Quantum Ultra mass spectrometry systems to discover biomarker proteins in the secreted fluids of cancer cell lines.
 
The company said that researcher Eleftherios Diamandis, who heads the division of clinical biochemistry in the University of Toronto’s department of medicine and pathobiology, expects the approach the group is using to help speed up the validation of biomarkers and targeted assays.
 
Ultimately, the company said, the research could lead to a reliable blood test for cancers, including breast and colon cancer.
 
The company also said the BRIMS center will work with UHN to maintain a cross-validation workflow to “legitimize” biomarkers that were first validated in Toronto, and then validated a second time at BRIMS.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.